Delivery Order SPE2DB20D3103-SPE2DB25FP6Q4
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $31,698.09 by the Defense Logistics Agency on July 31, 2025, for the supply of Eliquis 5 mg tablets (60-count). The award utilizes a firm fixed-price contract structure with an ultimate completion date of August 1, 2025, and carries no set-aside designation, indicating it was awarded through open competition. This delivery order is issued under...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a $17,176.10 delivery order from the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Eliquis 5 mg tablets (60-count). This firm fixed-price, competitively awarded contract represents a child award under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order carries no set-aside...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a firm fixed-price delivery order valued at $95,223.63 by the Defense Logistics Agency (DLA) for the supply of Eliquis 5 mg tablets (60-count units). The contract, awarded August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-competitive, open-market award. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $8,156.88 by the Defense Logistics Agency Medical Supply Chain on July 25, 2025, for the supply of Eliquis 5 mg tablets (60-count). The contract represents a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and is being performed at the contractor's corporate office in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation and is a child contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on July 22, 2025, for the supply of Eliquis 5 mg tablets in quantities of 60-tablet packages. This firm fixed-price delivery order, valued at $39,593.14, is a non-set-aside award issued under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order by the Defense Logistics Agency on July 24, 2025, for 60 tablets of Eliquis 2.5 mg with a ceiling value of $1,989.38. This non-competitive delivery order is set to be completed by July 25, 2025, and represents a pharmaceutical supply requisition under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract award supports the Defense...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Eliquis 5 mg tablets (60-count) with a ceiling value of $5,382.14. This is a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen...
- AmerisourceBergen Drug Corp received a delivery order award from the Defense Logistics Agency (DLA) on July 28, 2025, for supply of Eliquis 5 mg tablets in quantities of 60-count packages. This competitively awarded, non-set-aside contract carries a ceiling value of $43,468.64 under firm fixed price terms, with an ultimate completion date of July 29, 2025. The place of performance is listed as the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 30, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed-price contract with a ceiling value of $22,937.52. The contract, which is set to be completed by July 31, 2025, represents a single delivery order supporting the Defense Medical Supply Chain, a component of the Department of Defense's healthcare procurement operations. This award was made through competitive procurement with no set-aside...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for 60 tablets of Eliquis 5 mg, valued at $5,817.26. The contract was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and utilizes firm fixed-price pricing with no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP6Q4Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,157.96 by the Defense Logistics Agency (DLA) on July 28, 2025, with an ultimate completion date of July 29, 2025. The award is for the supply of Eliquis 5 mg tablets in a 60-count quantity, representing a firm fixed price, competitively awarded delivery order with no set-aside designation. This contract award is executed as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The delivery order reflects AmerisourceBergen's established role as a critical federal medical procurement vendor within the Defense Logistics Agency's Medical Supply Chain. Eliquis, an anticoagulant medication used for stroke prevention and treatment of blood clots, is typical of the specialty pharmaceutical products the company supplies to support military and veteran healthcare systems. The contract's execution from place of performance in Conshohocken, Pennsylvania demonstrates AmerisourceBergen's capacity to fulfill federal pharmaceutical requirements through its existing infrastructure and distribution network, consistent with its portfolio of competitively awarded federal contracts spanning a broad spectrum of therapeutic domains for Department of Defense health programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.2k | 7/28/25 |